The Mosaic Company (MOS) Investor Day 2025 summary

Strategic Vision and Business Transformation

• Leadership has redefined growth strategy around commodity production, market access, and ag technology, emphasizing digital transformation and operational excellence for value creation over the next five years.

• Market access is a core differentiator, with tailored strategies in North America, Brazil, China, and India, aiming for $300 million EBITDA uplift by 2030 through performance products and expanded distribution.

• Biosciences is positioned as a major growth engine, targeting $200 million EBITDA by 2030 and a long-term aspiration of $250–$500 million, leveraging proprietary biological products, R&D, and integration with fertilizer offerings.

• Capital allocation is shifting away from low-return assets, with $2–$3 billion in reallocation opportunities identified, including asset sales, product mix upgrades, and a focus on high-return, low-capex projects.

• No significant M&A is planned; excess cash will be returned to shareholders through dividends and buybacks, with a preference for buybacks at current valuation levels.

Market Outlook and Operational Improvements

• Global demand for phosphate and potash is projected to grow 8–10% by 2030, driven by population growth, biofuels, and declining arable land per capita, with supply constraints expected to keep markets tight.

• Chinese phosphate exports are expected to decline, tightening global supply, while new supply additions in both phosphate and potash are limited and slow to ramp up.

• Operational recovery is underway, with asset reliability improvements and targeted investments expected to restore phosphate production to 8 million tons by 2026 and potash to 9 million tons per year.

• Cost reduction initiatives in Brazil and technology upgrades in North America are projected to deliver $100–$150 million in savings and improved margins.

• Digital transformation, including SAP S/4HANA, AI-driven supply chain and pricing tools, and a digital acceleration program, is expected to yield $70 million in run-rate savings by year-end and $650 million in EBITDA uplift by 2026.

Financial Guidance and Capital Allocation

• Targeting a 55% increase in adjusted EBITDA by 2030, reaching $3.3–$3.5 billion, largely independent of fertilizer prices and without major investments.

• Projecting $2–$3 billion cumulative free cash flow (2025–2030) in low scenarios, up to $12–$13.3 billion in high scenarios, plus $2–$3 billion from capital reallocation.

• Committed to maintaining investment grade credit rating, with net debt/adjusted EBITDA at 1.8x and interest coverage at 9.0x at YE 2024.

• Targeting sustaining capex below $850 million by 2030 and prioritizing high-return, capital-light growth ($100–$200 million/year).

• Adjusted EBITDA improvement driven by production/cost normalization ($650–$800 million), market access ($250–$330 million), and growth initiatives ($150–$250 million) by 2030.